

Partner, Hong Kong

Investment Management



T: 852.3740.4880
geoffrey.chan@skadden.com

Education

J.D., Stanford Law School, 2004

B.Com, University of Toronto, Trinity College, 1998

Bar Admissions

Hong Kong

New York

Languages

English

Mandarin

Cantonese

Publications

"How, When and Why to Use the Corporate Venture Capital (CVC) Model," *China Law & Practice*, July 2024

"Secondary Solutions in Asia: Navigating Regulatory Clampdowns," *China Law & Practice*, June 2023

"The Hong Kong Limited Partnership Fund — An Attractive Alternative During an Economic Downturn," *China Law & Practice*, December 2022

Geoffrey Chan is head of Skadden's Asia Investment Management Group. He is a leading private funds lawyer with significant experience in structuring and forming private equity and venture capital funds for Asia-based managers, especially in China and Hong Kong, covering Asia-based investment advisers and institutional LPs since 2005.

Mr. Chan has represented a variety of investment advisers and sponsors throughout Asia in fund formation and other related internal funds issues. In addition, Mr. Chan regularly represents institutional investors in their commitments to Asia-based private equity funds and other alternative investment vehicles.

Prior to joining Skadden, Mr. Chan was the head of the Asian private funds practice of another leading U.S. law firm.

Mr. Chan is a frequent speaker at trade conferences on key issues related to the private funds formation industry.

Mr. Chan's clients have included:

- Asia Investment Capital
- Cenova Health
- China Media Capital
- CITIC Private Equity
- Cowin Capital
- FountainVest Partners
- HOPU Capital
- Mars, Inc.
- RRJ Capital
- Sky9 Capital
- Unicorn Capital

Leading international legal publications, including *Who's Who Legal*, *Chambers*, *The Legal 500* and *IFLR1000*, have repeatedly named Mr. Chan as a leading lawyer in Asia Pacific. He has also been named in *The International Who's Who of Private Funds Lawyers* and was selected to *China Business Law Journal's A-List* in 2025, 2024 and 2022.